Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Work In Process (2023 - 2026)

Cytosorbents filings provide 3 years of Work In Process readings, the most recent being $1.0 million for Q4 2025.

  • On a quarterly basis, Work In Process rose 101.59% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 101.59% increase, with the full-year FY2025 number at $1.0 million, up 101.59% from a year prior.
  • Work In Process hit $1.0 million in Q4 2025 for Cytosorbents, down from $1.1 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $1.1 million in Q3 2025 to a low of $503000.0 in Q4 2024.
  • Median Work In Process over the past 3 years was $810435.5 (2023), compared with a mean of $814904.5.
  • Biggest five-year swings in Work In Process: plummeted 40.04% in 2024 and later soared 101.59% in 2025.
  • Cytosorbents' Work In Process stood at $838871.0 in 2023, then plummeted by 40.04% to $503000.0 in 2024, then skyrocketed by 101.59% to $1.0 million in 2025.
  • The last three reported values for Work In Process were $1.0 million (Q4 2025), $1.1 million (Q3 2025), and $782000.0 (Q2 2025) per Business Quant data.